Service d'Endocrinologie, Diabète et Médecine de la Reproduction, Hôpital de l'Archet, CHU de Nice, 151, route de Saint-Antoine-de-Ginestière, BP 3079, 06202 Nice cedex 3, France.
Diabetes Metab. 2011 Nov;37(5):419-25. doi: 10.1016/j.diabet.2011.01.004. Epub 2011 Apr 12.
Currently, there is no international consensus for gestational diabetes mellitus (GDM) diagnosis. This is a report of our experience of GDM screening according to the 1996 French guidelines.
For 5 years, all pregnant women followed at our hospital (n=11,545) were prospectively screened for GDM between weeks 24 and 28 of pregnancy with a two-step strategy: the O'Sullivan test (OS) with a threshold at 130 mg/dL, followed by a 100-g OGTT if positive. GDM was diagnosed according to Carpenter and Coustan criteria.
Prevalence of GDM was 4.26% [344/1451 of patients with an OS of 130-199 mg/dL (12.1%); and 148 patients with an OS greater than 200 mg/dL]. The false-positive rate for the OS was 76.8%. Compared with 140 mg/dL, a threshold of 130 mg/dL caused 401 additional negative OGTTs in 90% of cases. In 80.7% GDM patients, fasting glucose was less than 95 mg/dL. The time lag between OS and OGTT was 3 weeks (1-84 days). Risk factors associated with GDM were maternal age, preconception overweight and obesity, parity, personal history of GDM or macrosomia, and familial history of obesity (P<0.05), but not diabetes. Also, 20% of GDM patients had no risk factors, whereas they were present in 75% of patients without GDM.
In our population, a two-step screening strategy for GDM was neither relevant nor efficient. It could be simplified with a single-step definitive screening strategy using a 75-g OGTT, as used in the HAPO study, and as recommended by the IADPSG and the recent French Expert Consensus. At present, there are still no evidence-based arguments to help in deciding between selective or universal screening for GDM.
目前,对于妊娠期糖尿病(GDM)的诊断尚无国际共识。本研究报告了根据 1996 年法国指南进行 GDM 筛查的经验。
在 5 年的时间里,我们对在我院就诊的所有孕妇(n=11545)进行前瞻性 GDM 筛查,采用两步策略:O'Sullivan 试验(OS),阈值为 130mg/dL,若阳性则进行 100gOGTT。根据 Carpenter 和 Coustan 标准诊断 GDM。
GDM 的患病率为 4.26%[130-199mg/dL 时 OS 为 130-199mg/dL 的患者有 1451 例中有 344 例(12.1%);OS 大于 200mg/dL 的患者有 148 例]。OS 的假阳性率为 76.8%。与 140mg/dL 相比,阈值为 130mg/dL 时,在 90%的情况下会导致 401 例不必要的阴性 OGTT。在 80.7%的 GDM 患者中,空腹血糖低于 95mg/dL。OS 和 OGTT 之间的时间差为 3 周(1-84 天)。与 GDM 相关的危险因素是母亲年龄、孕前超重和肥胖、产次、个人 GDM 或巨大儿史以及肥胖家族史(P<0.05),但与糖尿病无关。此外,20%的 GDM 患者没有危险因素,而在没有 GDM 的患者中,有 75%存在危险因素。
在我们的人群中,两步 GDM 筛查策略既不相关也不高效。可以采用一步法进行简化,即使用 HAPO 研究中使用的、IADPSG 和最近的法国专家共识推荐的 75gOGTT 进行确定性筛查。目前,对于选择性或普遍性 GDM 筛查,仍没有基于证据的论据来帮助做出决策。